摘要
目的:观察口服枳实薤白桂枝汤加减对稳定型冠心病的疗效。方法:选取江西中医药大学第二附属医院2020年1月至2021年1月门诊及住院部诊断为稳定型冠心病共80例,分为对照组与观察组,分别40例。对照组西医内科规范治疗,观察组在对照组基础上加用枳实薤白桂枝汤加减治疗。通过对比两组治疗前后心脏运动耐量、心绞痛积分、中医症候积分、血管内皮生长因子(VEGF)、血清内皮素-1(ET-1)和C反应蛋白(CRP)水平来对比两组治疗效果。结果:观察组治疗后心脏运动耐量、VEGF水平高于对照组,差异有统计学意义(P<0.05);而心绞痛积分、中医症候积分、ET-1和CRP水平低于对照组,差异有统计学意义(P<0.05)。结论:枳实薤白桂枝汤加减治疗稳定型冠心病疗效更佳,在稳定病变、减少不良反应及改善预后方面显示出一定的优势。
Objective:To observe the effect of zhishi xiebai guizhi decoction on stable coronary heart disease.Methods:From January 2020 to January 2021,a total of 80 patients were selected from the outpatient department and the inpatient department of The Second Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine,who were diagnosed as stable,coronary heart disease and divided into the control group and the observation group,with 40 cases respectively.The control group was treated with standard medical treatment,and the observation group was treated with zhishi xiebai guizhi decoction plus oral administration on the basis of the control group.Cardiac exercise tolerance,angina pectoris score,TCM syndrome score,vascular endothelial growth factor(VEGF),serum endothelin-1(ET-1)and C-reactive protein(CRP)levels were compared between the two groups before and after treatment to observe the curative effect.Results:Cardiac exercise tolerance and VEGF levels in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).The levels of angina pectoris score,TCM syndrome score,ET-1 and CRP were lower than those in the control group,the differences were statistically significant(P<0.05).Conclusion:Zhishi xiebai guizhi decoction is more effective in the treatment of stable coronary heart disease,and has certain advantages in stabilizing pathological changes,reducing adverse reactions and improving prognosis.
作者
聂志敏
刘中勇
陈智华
黄长水
刘火林
NIE Zhimin;LIU Zhongyong;CHEN Zhihua;HUANG Changshui;LIU Huolin(The Second Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine,Nanchang Jiangxi 330001,China)
出处
《药品评价》
CAS
2022年第5期293-295,共3页
Drug Evaluation
基金
江西省中医药科技计划一般项目(2020A0176)。
关键词
枳实薤白桂枝汤
稳定型冠心病
C反应蛋白
疗效
Zhishi xiebai guizhi decoction
Stable coronary heart disease
C-reactive protein(CRP)
Curative effect